Biotech Values

[poorgradstudent]

TRIL:

I would have thought by now there are fairly standard linkers that are not antigenic. Interaction between the linker and adjacent protein i can see forming a new epitope but a linker that is tried and true causing an immune reaction was not a concern I had

Worth pointing out that you can create de novo epitopes not simply due to changes in primary sequence but also due to changes in structure. So it may be easy to string together a bunch of glycine / alanine type residues in a known sequence in between two proteins, but sometimes you create novel structural elements that can be antigenic.

I'm not saying TRIL shareholders should be biting their fingernails on this point. It's just part of a mental checklist i have when companies are injecting proteins into people for therapeutic purposes.